Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer

Breast Cancer Research and Treatment

Volumn 131, Issue 3, 2012, Pages 849-858

  Tan, Min Han ^a   De, Sarmishtha ^a   Bebek, Gurkan ^a,b   Orloff, Mohammed S ^a,c   Wesolowski, Robert ^c   Downs Kelly, Erinn ^a   Budd, G Thomas ^b,c   Stark, George R ^a,b   Eng, Charis ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Chemotherapy resistance; Docetaxel; Kinesins; Paclitaxel; Taxanes

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; KINESIN; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA MODIFICATION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KIF12 GENE; KIF5A GENE; KIFC3 GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CELL LINE, TUMOR; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEK293 CELLS; HUMANS; KINESIN; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROTEIN BINDING; TAXOIDS; VINCRISTINE;

EID: 84856216595     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1500-8     Document Type: Article

References (31)

1. K Shalli I Brown SD Heys AC Schofield 2005 Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel FASEB J 19 10 1299 1301 10.1096/fj.04-3178fje 15946994 1:CAS:528:DC%2BD2MXntlWiurY%3D
2. C Dumontet BI Sikic 1999 Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death J Clin Oncol 17 3 1061 1070 10071301 1:CAS:528:DyaK1MXhvFGnsr8%3D
3. K Kamath L Wilson F Cabral MA Jordan 2005 BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability J Biol Chem 280 13 12902 12907 10.1074/jbc.M414477200 15695826 10.1074/jbc.M414477200 1:CAS:528:DC%2BD2MXislygsLo%3D
4. JA Bauer AB Chakravarthy JM Rosenbluth D Mi EH Seeley N De Matos Granja-Ingram MG Olivares MC Kelley IA Mayer IM Meszoely JA Means-Powell KN Johnson CJ Tsai GD Ayers ME Sanders RJ Schneider SC Formenti RM Caprioli JA Pietenpol 2010 Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation Clin Cancer Res 16 2 681 690 10.1158/1078-0432.CCR-09- 1091 20068102 10.1158/1078-0432.CCR-09-1091 1:CAS:528:DC%2BC3cXktF2qtL4%3D
5. F Andre C Hatzis K Anderson C Sotiriou C Mazouni J Mejia B Wang GN Hortobagyi WF Symmans L Pusztai 2007 Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer Clin Cancer Res 13 7 2061 2067 10.1158/1078-0432.CCR-06-2078 17404087 10.1158/1078-0432.CCR-06-2078 1:CAS:528:DC%2BD2sXjs12rtrY%3D
6. BT McGrogan B Gilmartin DN Carney A McCann 2008 Taxanes, microtubules and chemoresistant breast cancer Biochim Biophys Acta 1785 2 96 132 10.1016/j.bbcan.2007.10.004 18068131 1:CAS:528:DC%2BD1cXkvFWlu78%3D
7. JC Chang EC Wooten A Tsimelzon SG Hilsenbeck MC Gutierrez R Elledge S Mohsin CK Osborne GC Chamness DC Allred P O'Connell 2003 Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 9381 362 369 10.1016/S0140-6736(03)14023-8 12907009 10.1016/S0140-6736(03)14023-8 1:CAS:528:DC%2BD3sXlvFGnsLo%3D
8. N Juul Z Szallasi AC Eklund Q Li RA Burrell M Gerlinger V Valero E Andreopoulou FJ Esteva WF Symmans C Desmedt B Haibe-Kains C Sotiriou L Pusztai C Swanton 2010 Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials Lancet Oncol 11 4 358 365 10.1016/S1470-2045(10)70018-8 20189874 10.1016/S1470-2045(10)70018-8 1:CAS:528:DC%2BC3cXjvF2nu70%3D
9. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov C Williams SX Zhu PE Lonning AL Borresen-Dale PO Brown D Botstein 2000 Molecular portraits of human breast tumours Nature 406 6797 747 752 10.1038/35021093 10963602 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D
10. M Martin J Mackey C Vogel 2007 Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer Breast 16 Suppl 2 S127 S131 10.1016/j.breast.2007.09.001 17923408 10.1016/j.breast.2007.09.001
11. T Lu MW Jackson AD Singhi ES Kandel M Yang Y Zhang AV Gudkov GR Stark 2009 Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB Proc Natl Acad Sci USA 106 38 16339 16344 10.1073/pnas.0908560106 19805303 10.1073/pnas.0908560106 1:CAS:528:DC%2BD1MXht1Kqur7E
12. S De R Cipriano MW Jackson GR Stark 2009 Overexpression of kinesins mediates docetaxel resistance in breast cancer cells Cancer Res 69 20 8035 8042 10.1158/0008-5472.CAN-09-1224 19789344 10.1158/0008-5472.CAN-09-1224 1:CAS:528:DC%2BD1MXht1ynurfO
13. N Hirokawa Y Noda 2008 Intracellular transport and kinesin superfamily proteins, KIFs: structure, function, and dynamics Physiol Rev 88 3 1089 1118 10.1152/physrev.00023.2007 18626067 10.1152/physrev.00023.2007 1:CAS:528:DC%2BD1cXpslKgsLg%3D
14. JK Lee C Coutant YC Kim Y Qi D Theodorescu WF Symmans K Baggerly R Rouzier L Pusztai 2010 Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer Clin Cancer Res 16 2 711 718 10.1158/1078-0432.CCR-09-2247 20068086 10.1158/1078-0432.CCR-09-2247 1:CAS:528:DC%2BC3cXktF2qtLw%3D
15. RH Shoemaker 2006 The NCI60 human tumour cell line anticancer drug screen Nat Rev Cancer 6 10 813 823 10.1038/nrc1951 16990858 10.1038/nrc1951 1:CAS:528:DC%2BD28XpvVCmu7c%3D
16. Coombes KR, Wang J, Baggerly KA (2007) Microarrays: retracing steps. Nat Med 13(11):1276-1277; author reply 1277-1278. doi: 10.1038/nm1107-1276b
17. Z Hu C Fan DS Oh JS Marron X He BF Qaqish C Livasy LA Carey E Reynolds L Dressler A Nobel J Parker MG Ewend LR Sawyer J Wu Y Liu R Nanda M Tretiakova A Ruiz Orrico D Dreher JP Palazzo L Perreard E Nelson M Mone H Hansen M Mullins JF Quackenbush MJ Ellis OI Olopade PS Bernard CM Perou 2006 The molecular portraits of breast tumors are conserved across microarray platforms BMC Genomics 7 96 10.1186/1471-2164-7-96 16643655 10.1186/1471-2164-7-96
18. WF Symmans F Peintinger C Hatzis R Rajan H Kuerer V Valero L Assad A Poniecka B Hennessy M Green AU Buzdar SE Singletary GN Hortobagyi L Pusztai 2007 Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J Clin Oncol 25 28 4414 4422 10.1200/JCO.2007.10.6823 17785706 10.1200/JCO.2007.10.6823
19. KN Ogston ID Miller S Payne AW Hutcheon TK Sarkar I Smith A Schofield SD Heys 2003 A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival Breast 12 5 320 327 14659147 10.1016/S0960-9776(03)00106-1
20. DP Silver AL Richardson AC Eklund ZC Wang Z Szallasi Q Li N Juul CO Leong D Calogrias A Buraimoh A Fatima RS Gelman PD Ryan NM Tung A De Nicolo S Ganesan A Miron C Colin DC Sgroi LW Ellisen EP Winer JE Garber 2010 Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer J Clin Oncol 28 7 1145 1153 10.1200/JCO.2009.22.4725 20100965 10.1200/JCO.2009.22.4725 1:CAS:528:DC%2BC3cXktF2ltLk%3D
21. P Farmer H Bonnefoi P Anderle D Cameron P Wirapati V Becette S Andre M Piccart M Campone E Brain G Macgrogan T Petit J Jassem F Bibeau E Blot J Bogaerts M Aguet J Bergh R Iggo M Delorenzi 2009 A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer Nat Med 15 1 68 74 10.1038/nm.1908 19122658 10.1038/nm.1908 1:CAS:528:DC%2BD1MXhtVyjsQ%3D%3D
22. R Tibshirani T Hastie B Narasimhan G Chu 2002 Diagnosis of multiple cancer types by shrunken centroids of gene expression Proc Natl Acad Sci USA 99 10 6567 6572 12011421 10.1073/pnas.082099299 1:CAS:528:DC%2BD38XjvFCktbg%3D
23. M Katoh 2005 Characterization of KIF12 gene in silico Oncol Rep 13 2 367 370 15643526 1:CAS:528:DC%2BD2MXhsVGru74%3D
24. T Nakata N Hirokawa 1995 Point mutation of adenosine triphosphate-binding motif generated rigor kinesin that selectively blocks anterograde lysosome membrane transport J Cell Biol 131 4 1039 1053 7490281 10.1083/jcb.131.4.1039 1:CAS:528:DyaK2MXptleku7g%3D
25. CE Kan JT Patton GR Stark MW Jackson 2007 p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21 Cancer Res 67 20 9862 9868 10.1158/0008-5472.CAN-07-0259 17942917 10.1158/0008-5472.CAN-07-0259 1:CAS:528:DC%2BD2sXhtFOnsbvN
26. L Wordeman M Wagenbach T Maney 1999 Mutations in the ATP-binding domain affect the subcellular distribution of mitotic centromere-associated kinesin (MCAK) Cell Biol Int 23 4 275 286 10.1006/cbir.1999.0359 10600236 10.1006/cbir.1999.0359 1:CAS:528:DyaK1MXnvFarsLc%3D
27. G Finak N Bertos F Pepin S Sadekova M Souleimanova H Zhao H Chen G Omeroglu S Meterissian A Omeroglu M Hallett M Park 2008 Stromal gene expression predicts clinical outcome in breast cancer Nat Med 14 5 518 527 10.1038/nm1764 18438415 10.1038/nm1764 1:CAS:528:DC%2BD1cXlsFCms7w%3D
28. Wennmalm K, Ostman A, Bergh J (2009) Stromal signature identifies basal breast cancers. Nat Med 15(3):237-238; author reply 238. doi: 10.1038/nm0309-237
29. CH Smorenburg A Sparreboom M Bontenbal J Verweij 2001 Combination chemotherapy of the taxanes and antimetabolites: its use and limitations Eur J Cancer 37 18 2310 2323 11720823 10.1016/S0959-8049(01)00309-4 1:CAS:528:DC%2BD3MXosFKgtLo%3D
30. JW Purcell J Davis M Reddy S Martin K Samayoa H Vo K Thomsen P Bean WL Kuo S Ziyad J Billig HS Feiler JW Gray KW Wood S Cases 2010 Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer Clin Cancer Res 16 2 566 576 10.1158/1078-0432.CCR-09-1498 20068098 10.1158/1078-0432.CCR-09-1498 1:CAS:528:DC%2BC3cXktF2qtrc%3D
31. R Woessner B Tunquist C Lemieux E Chlipala S Jackinsky W Dewolf Jr W Voegtli A Cox S Rana P Lee D Walker 2009 ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models Anticancer Res 29 11 4373 4380 20032381 1:CAS:528:DC%2BC3cXptlemug%3D%3D